ABVC BioPharma Emphasizes Safety of Plant-Based ADHD Candidate Amid Rising Concerns About Psychiatric Polypharmacy
TL;DR
ABVC BioPharma's plant-based ADHD drug ABV-1505 offers a competitive edge with its non-addictive, non-stimulant profile that may reduce long-term medication burden compared to conventional treatments.
ABV-1505 is a botanical extract from Polygala tenuifolia that works as a non-stimulant ADHD treatment, showing efficacy in Phase II trials with no serious adverse events reported.
ABVC's plant-based ADHD candidate ABV-1505 could make tomorrow better by providing safer treatment options that reduce the need for multiple psychiatric medications over a patient's lifetime.
ABVC BioPharma is developing a plant-based ADHD drug from Polygala tenuifolia that shows promise as a non-addictive alternative to traditional stimulant medications.
Found this article helpful?
Share it with your network and spread the knowledge!
ABVC BioPharma, Inc. has addressed growing concerns about psychiatric polypharmacy in attention-deficit/hyperactivity disorder treatment by emphasizing the safety-focused approach of its plant-based drug candidate ABV-1505. Recent media reports have highlighted an increasing trend where children and adolescents who begin ADHD medications are more likely than the general population to later receive additional psychiatric drug prescriptions, raising questions about long-term treatment strategies and safety.
The company's ADHD program centers on ABV-1505, a botanical extract derived from Polygala tenuifolia that differs from traditional stimulant or amphetamine-based therapies. According to ABVC, ABV-1505 is plant-based, non-stimulant, not shown to cause addiction or dependency, and has not demonstrated drug-related serious adverse events in clinical studies. The candidate is designed to potentially reduce the likelihood of escalating to multi-drug psychiatric regimens.
ABV-1505 has completed a Phase II clinical trial at the University of California, San Francisco, which showed statistically significant improvement on ADHD rating scales compared with placebo, with the treatment being well tolerated and no serious safety concerns observed. The company is preparing the next phase of clinical development in collaboration with global partners.
Dr. Uttam Patil, ABVC's Chief Executive Officer, stated that growing concerns about long-term psychiatric medication burden highlight the need for safer, non-stimulant, and non-habit-forming ADHD treatment options. He noted that many families are searching for therapies that can help manage ADHD symptoms without increasing the risk of additional psychiatric medications later in life.
Recent media coverage, including articles from The Wall Street Journal, has drawn attention to this emerging issue. The Wall Street Journal article referenced multiple anecdotal accounts from individuals who began ADHD medication at a young age and ultimately received numerous additional psychiatric drug prescriptions over time. Other analyses published by major U.S. media outlets, including CNN and additional CNN coverage, have contributed to the national conversation about this pattern.
These media-reported stories underscore increasing public awareness of the potential long-term medication burden associated with conventional stimulant therapies and the need for safer therapeutic alternatives. The development of ABV-1505 represents an effort to address this unmet clinical and social need by exploring whether an effective treatment can also offer a cleaner and safer tolerability profile.
While more research is required, the clinical findings to date are encouraging according to company leadership. ABVC believes ABV-1505 represents a meaningful step toward expanding the treatment toolbox available to patients and healthcare providers seeking alternatives to traditional ADHD medications that may contribute to psychiatric polypharmacy concerns.
Curated from NewMediaWire
